Effectiveness of pneumococcal polysaccharide vaccine in older adults

被引:433
作者
Jackson, LA
Neuzil, KM
Yu, OC
Benson, P
Barlow, WE
Adams, AL
Hanson, CA
Mahoney, LD
Shay, DK
Thompson, WW
机构
[1] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA
[6] Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA
关键词
D O I
10.1056/NEJMoa022678
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Streptococcus pneumoniae is the chief cause of pneumonia in older adults, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall risk of community-acquired pneumonia. In a large population of older adults, we assessed the effectiveness of the pneumococcal vaccine. METHODS: In this retrospective cohort study, 47,365 Group Health Cooperative members 65 years of age or older were assessed over a three-year period. The primary outcomes were hospitalization because of community-acquired pneumonia (validated by chart review), pneumonia in patients who were not hospitalized (``outpatient pneumonia,'' determined from administrative data sources), and pneumococcal bacteremia. The association between pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazards models, with adjustment for age, sex, nursing-home residence or nonresidence, smoking status, medical conditions, and receipt or nonreceipt of influenza vaccine. RESULTS: During the study period, 1428 cohort members were hospitalized with community-acquired pneumonia, 3061 were assigned a diagnosis of outpatient pneumonia, and 61 had pneumococcal bacteremia. Receipt of the pneumococcal vaccine was associated with a significant reduction in the risk of pneumococcal bacteremia (hazard ratio, 0.56; 95 percent confidence interval, 0.33 to 0.93) but a slightly increased risk of hospitalization for pneumonia (hazard ratio, 1.14; 95 percent confidence interval, 1.02 to 1.28). Pneumococcal vaccination did not alter the risk of outpatient pneumonia (hazard ratio, 1.04; 95 percent confidence interval, 0.96 to 1.13) or of any case of community-acquired pneumonia, whether or not it required hospitalization (hazard ratio, 1.07; 95 percent confidence interval, 0.99 to 1.14). CONCLUSIONS: These findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention of bacteremia, but they suggest that alternative strategies are needed to prevent nonbacteremic pneumonia, which is a more common manifestation of pneumococcal infection in elderly persons.
引用
收藏
页码:1747 / 1755
页数:9
相关论文
共 39 条
[1]  
*ADM COMM IMM PRAC, 1997, MMWR-MORBID MORTAL W, V46, P1
[2]   COMMUNITY-ACQUIRED PNEUMONIA [J].
BARTLETT, JG ;
MUNDY, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1618-1624
[3]   Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia [J].
Black, SB ;
Shinefield, HR ;
Ling, S ;
Hansen, J ;
Fireman, B ;
Spring, D ;
Noyes, J ;
Lewis, E ;
Ray, P ;
Lee, J ;
Hackell, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) :810-815
[4]   Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients [J].
Breiman, RF ;
Keller, DW ;
Phelan, MA ;
Sniadack, DH ;
Stephens, DS ;
Rimland, D ;
Farley, MM ;
Schuchat, A ;
Reingold, AL .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2633-2638
[5]   The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection [J].
Briles, DE ;
Hollingshead, S ;
Brooks-Walter, A ;
Nabors, GS ;
Ferguson, L ;
Schilling, M ;
Gravenstein, S ;
Braun, P ;
King, J ;
Swift, A .
VACCINE, 2000, 18 (16) :1707-1711
[6]   Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA [J].
Briles, DE ;
Hollingshead, SK ;
King, J ;
Swift, A ;
Braun, PA ;
Park, MK ;
Ferguson, LM ;
Nahm, MH ;
Nabors, GS .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (06) :1694-1701
[7]  
Centers for Disease Control and Prevention, 2000, ACT BACT COR SURV AB
[8]   Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults:: a meta-analysis of randomized trials [J].
Cornu, C ;
Yzèbe, D ;
Léophonte, P ;
Gaillat, J ;
Boissel, JP ;
Cucherat, M .
VACCINE, 2001, 19 (32) :4780-4790
[9]   PNEUMOCOCCAL INFECTION AND IMMUNOLOGICAL RESPONSE TO PNEUMOCOCCAL VACCINE IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - A PILOT-STUDY [J].
DAVIS, AL ;
ARANDA, CP ;
SCHIFFMAN, G ;
CHRISTIANSON, LC .
CHEST, 1987, 92 (02) :204-212
[10]  
*DEP HLTH HUM SERV, 1980, DHHS PUBL PHS